JP2024045327A5 - - Google Patents

Download PDF

Info

Publication number
JP2024045327A5
JP2024045327A5 JP2024009895A JP2024009895A JP2024045327A5 JP 2024045327 A5 JP2024045327 A5 JP 2024045327A5 JP 2024009895 A JP2024009895 A JP 2024009895A JP 2024009895 A JP2024009895 A JP 2024009895A JP 2024045327 A5 JP2024045327 A5 JP 2024045327A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
val
phe
lys
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024009895A
Other languages
English (en)
Japanese (ja)
Other versions
JP7664437B2 (ja
JP2024045327A (ja
Filing date
Publication date
Priority claimed from PCT/US2019/034114 external-priority patent/WO2019231879A1/en
Application filed filed Critical
Publication of JP2024045327A publication Critical patent/JP2024045327A/ja
Publication of JP2024045327A5 publication Critical patent/JP2024045327A5/ja
Application granted granted Critical
Publication of JP7664437B2 publication Critical patent/JP7664437B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024009895A 2018-05-29 2024-01-26 プロドラッグおよび複合体に使用する修飾自己切断部分ならびにその使用方法および製造方法 Active JP7664437B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862677307P 2018-05-29 2018-05-29
US62/677,307 2018-05-29
PCT/US2019/034114 WO2019231879A1 (en) 2018-05-29 2019-05-28 Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making
JP2020566576A JP7458997B2 (ja) 2018-05-29 2019-05-28 プロドラッグおよび複合体に使用する修飾自己切断部分ならびにその使用方法および製造方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020566576A Division JP7458997B2 (ja) 2018-05-29 2019-05-28 プロドラッグおよび複合体に使用する修飾自己切断部分ならびにその使用方法および製造方法

Publications (3)

Publication Number Publication Date
JP2024045327A JP2024045327A (ja) 2024-04-02
JP2024045327A5 true JP2024045327A5 (https=) 2024-06-24
JP7664437B2 JP7664437B2 (ja) 2025-04-17

Family

ID=66912963

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020566576A Active JP7458997B2 (ja) 2018-05-29 2019-05-28 プロドラッグおよび複合体に使用する修飾自己切断部分ならびにその使用方法および製造方法
JP2024009895A Active JP7664437B2 (ja) 2018-05-29 2024-01-26 プロドラッグおよび複合体に使用する修飾自己切断部分ならびにその使用方法および製造方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020566576A Active JP7458997B2 (ja) 2018-05-29 2019-05-28 プロドラッグおよび複合体に使用する修飾自己切断部分ならびにその使用方法および製造方法

Country Status (13)

Country Link
US (3) US10898578B2 (https=)
EP (1) EP3801629A1 (https=)
JP (2) JP7458997B2 (https=)
KR (1) KR102932312B1 (https=)
CN (1) CN112188902A (https=)
AU (2) AU2019277094B2 (https=)
BR (1) BR112020024022A2 (https=)
CA (1) CA3101601A1 (https=)
EA (1) EA202092747A1 (https=)
IL (3) IL312163B2 (https=)
MX (1) MX2020012674A (https=)
SG (1) SG11202011739SA (https=)
WO (1) WO2019231879A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112188902A (zh) * 2018-05-29 2021-01-05 百时美施贵宝公司 用于前药和缀合物的经修饰的自消灭部分以及使用和制造方法
EP3954382A4 (en) * 2019-04-05 2022-12-21 Sumitomo Pharma Co., Ltd. WATER SOLUBLE ADJUVANT AND COMPOSITION CONTAINING IT
KR20220024106A (ko) * 2019-05-20 2022-03-03 노파르티스 아게 Mcl-1 억제제 항체-약물 접합체 및 사용 방법
AU2022286137A1 (en) * 2021-06-01 2023-12-14 Ajinomoto Co., Inc. Conjugate of antibody and functional substance or salt of said conjugate, and compound for use in production of said conjugate or salt of said compound
AU2022353331A1 (en) * 2021-09-30 2024-04-11 Ajinomoto Co., Inc. Regioselective conjugate of functional substance and antibody or salt of said conjugate, and antibody derivative and compound for use in production of said conjugate, or salt of said antibody derivative and compound
CN116199740A (zh) * 2021-12-01 2023-06-02 上海生物制品研究所有限责任公司 抗体药物偶联物及其用途
KR102835630B1 (ko) * 2022-02-25 2025-07-22 앱티스 주식회사 신규 항체 약물 접합체
JP2026500913A (ja) 2022-12-13 2026-01-09 クリネティックス ファーマシューティカルズ，インク． ソマトスタチンサブタイプ－２受容体（ｓｓｔ２ｒ）標的化治療薬及びその使用
CN120418281A (zh) * 2022-12-29 2025-08-01 财团法人生物技术开发中心 靶向PD-L1和中和Gas6之融合蛋白及其用途
CN120882431A (zh) * 2023-01-11 2025-10-31 金麦安博股份有限公司 接头、药物接头及其缀合物和使用它们的方法
WO2026046186A1 (en) * 2024-08-27 2026-03-05 Suzhou Bioreinno Biotechnology Limited Company Linkers, linker conjugates and conjugate compounds thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US828678A (en) 1902-09-05 1906-08-14 Roberto Taeggi Piscicelli Electric telpher postal system.
CA104587A (en) 1906-12-24 1907-04-09 Thomas Henry Cole Apparatus for generating and storing products of combustion under pressure
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
EP1471938A4 (en) 2002-01-09 2008-03-05 Medarex Inc HUMAN MONOCLONAL ANTIBODIES AGAINST CD30
GB0220319D0 (en) * 2002-09-02 2002-10-09 Cancer Res Campaign Tech Enzyme activated self-immolative nitrogen mustard drugs
GT200400138A (es) 2003-07-22 2005-03-22 Anticuerpos rgi y uso de los mismos.
RS53984B1 (sr) 2003-12-10 2015-10-30 E. R. Squibb & Sons L.L.C. Ip-10 antitela i njihove upotrebe
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
RU2402548C2 (ru) 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
BRPI0607796A2 (pt) 2005-02-18 2009-06-13 Medarex Inc composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica
NZ556661A (en) 2005-02-18 2010-10-29 Medarex Inc Human monoclonal antibodies to prostate specific membrance antigen (PSMA)
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
CA2623236A1 (en) 2005-09-26 2007-04-05 Medarex, Inc. Human monoclonal antibodies to cd70
AU2006321553B2 (en) 2005-12-08 2012-03-08 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to O8E
EA017812B1 (ru) 2005-12-08 2013-03-29 Медарекс, Инк. Выделенное моноклональное антитело или его антигенсвязывающий участок, которые связываются с протеинтирозинкиназой 7 ( ptk7) человека, и их применение
US8383118B2 (en) 2005-12-08 2013-02-26 Medarex, Inc. Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1
WO2007103288A2 (en) 2006-03-02 2007-09-13 Seattle Genetics, Inc. Engineered antibody drug conjugates
DK2035554T3 (da) 2006-06-29 2013-06-17 Univ Leland Stanford Junior Celle-fri syntese af proteiner indeholdende ikke-naturlige aminosyrer
JP2010500886A (ja) 2006-08-18 2010-01-14 ノボ ノルディスク ヘルス ケア アーゲー 改善された特異性を有するトランスグルタミナーゼ変異体
EP2064316B1 (en) 2006-09-08 2012-01-25 Ambrx, Inc. Site specific incorporation of non-natural amino acids by vertebrate cells
KR101722261B1 (ko) 2006-10-02 2017-04-03 메다렉스, 엘.엘.시. Ｃｘｃｒ4에 결합하는 인간 항체 및 이의 용도
WO2008067495A2 (en) * 2006-11-29 2008-06-05 Rutgers, The State University Of New Jersey Chemotherapeutic conjugates and methods of use
KR101552735B1 (ko) 2006-12-01 2015-09-14 메다렉스, 엘.엘.시. 씨디22에 결합하는 인간 항체 및 이의 용도
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
KR20090123857A (ko) 2007-02-22 2009-12-02 노보 노르디스크 헬스 케어 악티엔게젤샤프트 특이성이 개선된 트랜스글루타미나아제 변이체
KR101570252B1 (ko) 2007-07-17 2015-11-19 메다렉스, 엘.엘.시. 글리피칸-3에 대한 단클론 항체
CA2700860C (en) 2007-10-01 2016-07-19 Jonathan A. Terrett Human antibodies that bind mesothelin, and uses thereof
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
US9676871B2 (en) 2010-11-05 2017-06-13 Pfizer Inc. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
US8828678B2 (en) 2010-11-16 2014-09-09 Enzo Life Sciences, Inc. Self-immolative probes for enzyme activity detection
WO2012113847A1 (en) * 2011-02-25 2012-08-30 Lonza Ltd Branched linker for protein drug conjugates
RU2015129800A (ru) 2012-12-21 2017-01-30 Биоэллаенс К. В. Гидрофильные саморазрушающиеся линкеры и их конъюгаты
RS56169B1 (sr) 2013-02-14 2017-11-30 Bristol Myers Squibb Co Jedinjenja tubulisina, metode pripreme i primena
KR20160068738A (ko) 2013-08-14 2016-06-15 윌리엄 마쉬 라이스 유니버시티 운시알라마이신의 유도체, 합성 방법 및 항종양 제제로서 이들의 용도
KR101628872B1 (ko) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
SI3900742T1 (sl) 2014-09-11 2024-10-30 Seagen Inc. Ciljana dostava zdravilnih snovi, ki vsebujejo terciarne amine
CN104587487B (zh) * 2015-01-06 2018-01-16 华东师范大学 一种应用于靶向给药系统的新的支链连接体
CN107406496A (zh) 2015-03-10 2017-11-28 百时美施贵宝公司 可通过转谷氨酰胺酶缀合的抗体和由其制备的缀合物
CN108472386A (zh) 2015-10-02 2018-08-31 百时美施贵宝公司 用于缀合抗体的转谷氨酰胺酶变体
EP3469000A1 (en) * 2016-06-08 2019-04-17 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
EP3458479B1 (en) * 2016-06-08 2020-11-04 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
BR112018075644A2 (pt) * 2016-06-08 2019-04-09 Abbvie Inc. anticorpos anti-cd98 e conjugados de anticorpo e fármaco
CN116173232A (zh) * 2016-06-08 2023-05-30 艾伯维公司 抗cd98抗体及抗体药物偶联物
CN112188902A (zh) * 2018-05-29 2021-01-05 百时美施贵宝公司 用于前药和缀合物的经修饰的自消灭部分以及使用和制造方法

Similar Documents

Publication Publication Date Title
JP2024045327A5 (https=)
JP2023038235A5 (https=)
ES2826398T3 (es) Enlazadores-fármacos pegilados para una mejor farmacocinética de los conjugados ligando-fármaco
ES2269160T3 (es) Procedimiento para la preparacion de una formulacion medicamentosa inyectable.
RU2017144859A (ru) Конъюгаты сконструированных антител с цистеиновыми заменами
RU94015842A (ru) Пептидные кетоны, фармацевтическая композиция и способ ингибирования интерлейкин-1 протеазы
JP2013533864A5 (https=)
JP2004537581A5 (https=)
RU2019105549A (ru) Гидрофильные саморазрушающиеся линкеры и их конъюгаты
JP2019172710A5 (https=)
ES2269397T3 (es) Sistemas de ligando terapeuticos y de diagnostico que comprenden propiedades de union a moleculas de transporte y medicamentos que los contienen.
JP2013540102A5 (https=)
JP2020520981A5 (https=)
JPWO2022228495A5 (https=)
FI900600A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten insuliinianalogien valmistamiseksi
JP2010501638A (ja) 修飾タンパク質
JP2016508136A5 (https=)
JPWO2022228494A5 (https=)
JP2018503639A5 (https=)
JP2013155195A5 (https=)
JP2002523466A5 (https=)
ES2624626T3 (es) Ligadores basados en tirosina para la conexión desprendible de péptidos
JP2004515471A (ja) 合成赤血球産生刺激タンパク質
EP3288593A1 (en) Conjugate of monomethyl auristatin f and trastuzumab and its use for the treatment of cancer
JP2013531660A5 (https=)